1 May 2010 – Nordic Group obtained exclusive marketing rights for Mitomycin-C, an antineoplastic agent by Kyowa Hakko Kirin.
Mitomycin – „Golden” standard in the treatment of superficial carcinoma of the bladder after a transurethral resection (TUR).
Therapeutic protocols for bladder cancer:
- Low risk tumours: 40 mg single instillation after transurethral resection (TUR) – “one shot”.
- Medium and high risk tumours: “one shot” therapy + maintenance therapy – 6-8 weeks/once a week + 6-8 months/once a month